📰 Breaking News: Lessons Learnt & Insights from DSTBTD Restructuring Plan

Resolution for winding up (MVL)

Novartis Europharm Limited enters members' voluntary liquidation

active Company no. 03068306 Published 08 October 2026

In short: Novartis Europharm Limited (company no. 03068306) entered members' voluntary liquidation, a solvent and planned closure, according to a Resolution for winding up (MVL) notice published in The London Gazette on 08 October 2026. The office holders are Derek Hyslop (IP No. 9970); Matthew Coomber (IP No. 24430), appointed 30 September 2026.

The shareholders of six companies passed resolutions on 30 September 2026 to voluntarily wind them up and appointed Ernst & Young LLP partners as joint liquidators.

Notice details

Company
NOVARTIS EUROPHARM LIMITED
Company number
03068306
Company
NOVARTIS GRIMSBY LIMITED
Company number
00170180
Company
GYROSCOPE THERAPEUTICS LIMITED
Company number
10131257
Company
GYROSCOPE THERAPEUTICS HOLDINGS LIMITED
Company number
13086765
Company
ADVANCED ACCELERATOR APPLICATIONS (UK & IRELAND) LIMITED
Company number
04189193
Registered office
1 More London Place, London, SE1 2AF
Principal trading address
2nd Floor, The Westworks Building White City Place, 195 Wood Lane, London, W12 7FQ
Liquidator(s)
Derek Hyslop (IP No. 9970); Matthew Coomber (IP No. 24430)
Liquidator firm
Ernst & Young LLP
Date of appointment
30 September 2026
Appointed by
Shareholders (special and ordinary resolutions)
Contact
The Joint Liquidators, Tel: 020 7951 6477
Alternative contact
Melanie Hellmuth. Johan Mikael Olof Kahlstroem, Director

What this notice means

A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.

Read more: What is Liquidation?.

All notices for Novartis Europharm Limited

3 Gazette notices on record for company no. 03068306, newest first. The full history, with last filed accounts, is on the Novartis Europharm Limited company record.

  1. Notices to creditors (MVL) 08 Oct 2026
  2. Appointment of liquidators (MVL) 08 Oct 2026

How does this notice affect you?

Choose what applies and we'll point you at the right next step.

Would rather just talk? 020 7720 8000

Related guidance

Free, practical guides from K2 on what this kind of notice means for directors.

More liquidation notices

← Back to all notices

Frequently asked questions

Is Novartis Europharm Limited in financial difficulty?

No — this is a solvent process. A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress. The London Gazette published a Resolution for winding up (MVL) for Novartis Europharm Limited (company no. 03068306) on 08 October 2026.

What does a Resolution for winding up (MVL) mean?

A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.

Who is dealing with the liquidation?

The office holders named in the notice: Derek Hyslop (IP No. 9970); Matthew Coomber (IP No. 24430), appointed 30 September 2026. Creditors, employees and anyone holding goods or money belonging to the company should contact them directly, quoting the company number.

Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.